Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/ijms22010037
Keywords
skeletal muscle; sarcoplasmic reticulum calcium-transporting ATPase; sarcopenia
Funding
- Irene Diamond Fund/AFAR Postdoctoral Transition Award in Aging
- VA Merit grant [I01BX004453-01A1]
- Senior Research Career Scientist Award from the Department of Veterans Affairs [12F-RCS-011]
Ask authors/readers for more resources
The study showed that pharmacological activation of SERCA can mitigate sarcopenia phenotype in aging mice, reversing reductions in muscle mass and force generation, and preventing an increase in mitochondrial ROS production. These effects are mediated in part by enhanced cellular energetics through activation of PGC1-alpha, UCP1, HSF1, and APMK, as well as increased regenerative capacity by suppression of MEF2C and p38 MAPK signaling.
Sarcopenia has a significant negative impact on healthspan in the elderly and effective pharmacologic interventions remain elusive. We have previously demonstrated that sarcopenia is associated with reduced activity of the sarcoplasmic reticulum Ca2+ ATPase (SERCA) pump. We asked whether restoring SERCA activity using pharmacologic activation in aging mice could mitigate the sarcopenia phenotype. We treated 16-month male C57BL/6J mice with vehicle or CDN1163, an allosteric SERCA activator, for 10 months. At 26 months, maximal SERCA activity was reduced 41% in gastrocnemius muscle in vehicle-treated mice but maintained in old CDN1163 treated mice. Reductions in gastrocnemius mass (9%) and in vitro specific force generation in extensor digitorum longus muscle (11%) in 26 versus 16-month-old wild-type mice were also reversed by CDN1163. CDN1163 administered by intra-peritoneal injection also prevented the increase in mitochondrial ROS production in gastrocnemius muscles of aged mice. Transcriptomic analysis revealed that these effects are at least in part mediated by enhanced cellular energetics by activation of PGC1-alpha, UCP1, HSF1, and APMK and increased regenerative capacity by suppression of MEF2C and p38 MAPK signaling. Together, these exciting findings are the first to support that pharmacological targeting of SERCA can be an effective therapy to counter age-related muscle dysfunction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available